The Role of Brentuximab Vedotin (BV) as Second-Line Treatment of Refractory Classical Hodgkin Lymphoma (cHL) in the Era of Pandemic COVID-19.
Wulyo RajabtoVitya ChandikaAgnes Stephanie HarahapMaria Francisca HamPublished in: International medical case reports journal (2022)
In this particular case of patient, BV as monotherapy can be an option during the pandemic COVID-19 for refractory cHL ineligible for second-line chemotherapy followed by HDT and ASCT.